Table 4.
Characteristics of presentation according to gender for patients with signal peptide or prosegment mutations.
| Female | Male | P value | |
|---|---|---|---|
| Individuals | 44 | 52 | 0.41 |
| Age at presentation1 < 10 | 18/35(48.6%) | 17/43(39.5) | 0.42 |
| Age at presentation1 10 to < 20 | 9/35(25.7%) | 12/43(27.9%) | 0.85 |
| Age at presentation1 >20 | 9/35(25.7) | 13/43(30.2%) | 0.66 |
| Age at presentation (mean±s.d.) | 19.9±19.4 | 19.3±13.7 | 0.6 |
| Anemia as child (%) | 31/32(96.7%) | 19/27(45.8%) | 0.005 |
| Gout(%) | 15/38(39.5%) | 29/37(49.3%) | 0.0006 |
| Age at first gout attack (mean±s.d.) | 30.3±9.6 | 27.8±9.7 | 0.45 |
| Age at ESKD onset (mean±s.d.) | 50.1±11.4 | 55.8±10.5 | 0.25 |
| Serum potassium (mEq/L) (mean±s.d.) | 5.1±0.5 | 5.1±0.6 | 0.75 |
| Serum bicarbonate (mEq/L) (mean±s.d.) | 21.3±0.4 | 22.2±2.5 | 0.38 |
| Serum urate (mg/dL) without urate-lowering therapy (mean±s.d.) | 7.7±1.6 | 9.4±2.7 | 0.02 |
1
Excluding individuals who presented for asymptomatic genetic screening.